Summit Financial LLC Has $244,000 Stock Holdings in GSK plc (NYSE:GSK)

Summit Financial LLC boosted its stake in shares of GSK plc (NYSE:GSK) by 45.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,128 shares of the pharmaceutical company’s stock after buying an additional 2,218 shares during the period. Summit Financial LLC’s holdings in GSK were worth $244,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of GSK. Indiana Trust & Investment Management Co raised its holdings in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in shares of GSK in the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its holdings in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares in the last quarter. Sunbelt Securities Inc. boosted its position in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Finally, Sierra Ocean LLC acquired a new position in shares of GSK during the fourth quarter worth about $32,000. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 6.5 %

NYSE GSK opened at $36.49 on Friday. The company has a market cap of $75.53 billion, a PE ratio of 22.95, a PEG ratio of 1.12 and a beta of 0.56. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The stock has a 50 day moving average of $37.63 and a 200-day moving average of $36.59. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.31%. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 98.74%.

Wall Street Analyst Weigh In

Several research firms have commented on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.